Flying High On Obesity Success, Novo’s Appetite For Deals Grows
By Natalie Grover LONDON (Reuters) – Buoyed by the success of its diabetes and obesity drugs, Novo Nordisk is on the prowl for partnerships and deals to beef up its pipeline, a senior company executive said on Thursday. John McDonald, corporate vice president of global R&D business development, said the Danish drugmaker aims to shed…
